Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 5
2009 6
2010 10
2011 8
2012 4
2013 7
2014 6
2015 13
2016 10
2017 13
2018 14
2019 20
2020 23
2021 24
2022 19
2023 25
2024 35
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Results by year

Filters applied: . Clear all
Page 1
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration.
Molina-Gonzalez I, Holloway RK, Jiwaji Z, Dando O, Kent SA, Emelianova K, Lloyd AF, Forbes LH, Mahmood A, Skripuletz T, Gudi V, Febery JA, Johnson JA, Fowler JH, Kuhlmann T, Williams A, Chandran S, Stangel M, Howden AJM, Hardingham GE, Miron VE. Molina-Gonzalez I, et al. Among authors: skripuletz t. Nat Commun. 2023 Jun 8;14(1):3372. doi: 10.1038/s41467-023-39046-8. Nat Commun. 2023. PMID: 37291151 Free PMC article.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: skripuletz t. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15. Autoimmun Rev. 2023. PMID: 36924922 Free article. Review.
Sjögren's syndrome with and without neurological involvement.
Seeliger T, Kramer E, Konen FF, Zehrfeld N, Beider S, Prenzler NK, Gödecke V, Witte T, Skripuletz T, Ernst D. Seeliger T, et al. Among authors: skripuletz t. J Neurol. 2023 Jun;270(6):2987-2996. doi: 10.1007/s00415-023-11613-5. Epub 2023 Feb 18. J Neurol. 2023. PMID: 36802030 Free PMC article.
[Neuroimmunology of COVID-19].
Skripuletz T, Möhn N, Franke C, Prüß H. Skripuletz T, et al. Nervenarzt. 2021 Jun;92(6):521-530. doi: 10.1007/s00115-021-01077-1. Epub 2021 Mar 2. Nervenarzt. 2021. PMID: 33651117 Free PMC article. Review. German.
Directly Isolated Allogeneic Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy.
Möhn N, Grote-Levi L, Wattjes MP, Bonifacius A, Holzwart D, Hopfner F, Nay S, Tischer-Zimmermann S, Saßmann ML, Schwenkenbecher P, Sühs KW, Mahmoudi N, Warnke C, Zimmermann J, Hagin D, Goudeva L, Blasczyk R, Koch A, Maecker-Kolhoff B, Eiz-Vesper B, Höglinger G, Skripuletz T. Möhn N, et al. Among authors: skripuletz t. JAMA Neurol. 2024 Oct 7;81(11):1187-98. doi: 10.1001/jamaneurol.2024.3324. Online ahead of print. JAMA Neurol. 2024. PMID: 39374035 Free PMC article.
Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset.
Konen FF, Gingele S, Hümmert MW, Möhn N, Streichert AL, Kretschmer JR, Grote-Levi L, Nay S, Seeliger T, Ratuszny D, Jendretzky KF, Tkachenko D, Jacobs R, Skripuletz T, Schwenkenbecher P. Konen FF, et al. Among authors: skripuletz t. Mult Scler Relat Disord. 2024 Nov;91:105886. doi: 10.1016/j.msard.2024.105886. Epub 2024 Sep 14. Mult Scler Relat Disord. 2024. PMID: 39299183 Free article.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
224 results